Healthcare / BiotechnologyBrussels
$5.18
+0.16 (+3.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-7.6M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$145M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.9%
↓Gross Margin
94.7%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+100.1%
FCF CAGR
—
FCF margin
-105.7%
FCF / Net income
1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.2M · net income $-6.3M · FCF $-7.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.2M | $7.2M | $8.5M | $2.1M | $900000.00 |
| Net Income | $-6.3M | $-6.3M | $-6.3M | $-15.4M | $-11.9M |
| EBITDA | $-5.9M | $-5.9M | $-5.6M | $-15.0M | $-11.5M |
| EPS | — | — | -0.23 | -0.56 | -0.43 |
| Gross Margin | 94.7% | 94.7% | 97.3% | 95.5% | 89.6% |
| Operating Margin | -107.0% | -107.0% | -75.3% | -759.3% | -1278.7% |
| Net Margin | -87.9% | -87.9% | -75.0% | -736.9% | -1322.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.06 | 0.04 | 0.02 |
| Current Ratio | 3.89 | 3.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.6M | $-7.6M | $-7.5M | $-13.6M | $-13.8M |
| Returns | |||||
| ROE | -23.9% | -23.9% | -19.7% | -39.4% | -22.1% |
| Valuation | |||||
| P/B | 5.48 | 5.48 | 5.47 | 9.53 | 5.79 |
| Growth & Yield | |||||
| Revenue Growth | -14.8% | -14.8% | 305.3% | 131.9% | — |
| EPS Growth | — | — | 59.1% | -30.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.23 → n/d
Residual
-17.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.